New Scientific Discovery: Kyojin Probiotic May Enhance the Effectiveness of Mucosal Vaccines
We are proud to announce that Kyojin was part of a recent international study published in the prestigious scientific journal Vaccines, edited by MDPI, which specializes in immunology and vaccine development.
The study, titled “Mucosal vaccination against SARS-CoV-2 using human probiotic Bacillus subtilis spores as an adjuvant induces potent systemic and mucosal immunity” (Vaccines, 2025), explores the use of Bacillus subtilis DG101 spores—found in Kyojin products—as a novel adjuvant in COVID-19 vaccines.
The research was conducted by a multidisciplinary team of scientists from Argentina, Cuba, Belgium, and the United Arab Emirates, and shows that this probiotic can stimulate both systemic immunity (IgG) and mucosal immunity (IgA)—something rarely achieved with current injectable vaccines.
This represents a significant breakthrough, as most modern vaccines only trigger immune responses in the bloodstream (IgG), but not in the mucous membranes—the main entry point for pathogens such as viruses, bacteria, and fungi. Mucosal vaccines, by contrast, aim to protect at the first point of contact, strengthening the body’s immediate line of defense.
In the preclinical study using animal models, Kyojin probiotic spores acted as an adjuvant, enhancing the effectiveness of the COVID-19 vaccine by generating humoral immunity, mucosal immunity, and—most importantly—immune memory, which is key to preventing reinfections and responding to new viral variants.
This kind of discovery not only paves the way for the development of more effective and safer vaccines, but also positions probiotics as innovative tools in the field of preventive immunology.
At Kyojin, we reaffirm our commitment to high-impact scientific research and are proud to be actively involved in projects that bridge biotechnological innovation with global health.
Read the full article in the journal Vaccines:
https://doi.org/10.3390/vaccines13070772
